Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- The Company’s cash and cash equivalents balance is approximately $4.8 million, down from $8 million. This change might result in funding challenges for operations.
- The Company raised approximately $1.5 million through ATM sales from July 1, 2024, to September 10, 2024. This change may impact liquidity and operational funding.
- The estimated total cash expenditure budget is approximately $7.9 million for July 2024 through October 2025, including $4.9 million for R&D. This change indicates increased financial commitment to drug development.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1379006&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.